FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026) Live odds across 1 market: a full approval or an accelerated approval a
Resolved
- a full approval or an accelerated approval: Yes 100¢ (kalshi)
TRADING OPEN
8sFDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)
Resolved
Total Volume
$3.8K
+$1.5K (24h)
Active Markets
1
Across 1 platforms
Frontrunner
100¢
a full approval or an accelerated approval
Biggest Mover 24h
+31¢
a full approval or an accelerated approval
Arb Opportunities
0
None detected
All Markets
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | 100¢ | 100¢ | $3.8K+$1.5K 24h | +31¢ | — |
Implied Probability
Consensus across platformsEvent Info
Whale Activity
Loading...